Maintenance therapy with low dose cyclophosphamide does not increase the risk of second malignancies: The European Pediatric Soft Tissue Sarcoma Study Group RMS2005 study experience
Oct 2026· Cancer· Vol 132· 0 citations· 15 references
Medicine
TL;DR
The addition of maintenance chemotherapy with low‐dose cyclophosphamide and vinorelbine has improved survival outcomes for patients with high‐risk disease, but the potential SMN risk from increased cumulative alkylating agent exposure remains unclear.
Abstract
Survivors of childhood rhabdomyosarcoma (RMS) are at increased risk of second malignant neoplasms (SMNs), influenced by treatment type and genetic predisposition. Recently, the addition of maintenance chemotherapy with low‐dose cyclophosphamide and vinorelbine has improved survival outcomes for patients with high‐risk disease. However, the potential SMN risk from increased cumulative alkylating agent exposure remains unclear.
The median overall survival (OS) for patients with recurrent or metastatic cervical cancer after progression on first-line therapy is only 5–12 months. We retrospectively reviewed four patients who received modified induction–maintenance therapy. All of the patients achieved clinical benefit to varying degrees, with on...
Yi-Qin Duan, Dan Liu, Qiang Huang et al.· Frontiers in Oncology· 0 citations
BACKGROUND
Outcomes for relapsed Ewing sarcoma remain poor. The RIST regimen (rapamycin, irinotecan, dasatinib, temozolomide) provides a targeted biological alternative to standard salvage chemotherapy.
METHODS
We report 3 patients treated with RIST for relapsed Ewing sarcoma.Results:One patient with measurable disea...
Mahdi Asleh, Yotam Eshel, M. Ben-Harosh et al.· Journal of pediatric hematol...· 0 citations
A multicentre Japanese cohort of patients with localised cutaneous angiosarcoma of the head and neck showed that combination therapy was associated with favourable outcomes. In patients achieving a complete response after concurrent chemoradiotherapy, maintenance chemotherapy was associated with prolonged progression-f...
E. Nakano, Yasuhiro Fujisawa, M. Masuzawa et al.· British Journal of Dermatolo...· 0 citations
The clinical case described concerns a 56-years old woman with triple-negative breast cancer metastic to bone progressed with previous chemotherapy and immunotherapy. Our patient, treated in second line with sacituzumab govitecan, obtained prolonged disease control without severe toxicity e with good quality of life.
Caterina Battaglia· Recenti progressi in medicin...· 0 citations
Simple Summary This retrospective study evaluated the effectiveness and safety of adding a programmed death-ligand 1 (PD-L1) inhibitor to platinum-based chemotherapy in patients aged ≥75 year with extensive-stage small cell lung cancer. The combination treatment significantly prolonged overall survival compared with ch...
Minoru Kobayashi, Satoshi Watanabe, S. Hirose et al.· Cancers· 0 citations
The role of neoadjuvant therapy in children, adolescents, and young adults (CAYA) with initially unresectable nonrhabdomyosarcoma soft tissue sarcoma (NRSTS) remains controversial, with recommendations varying by cooperative group. The International Soft Tissue Sarcoma Consortium (INSTRuCT) is a collaboration among Nor...
A. Weiss, James R. Anderson, Sonja D. Chen et al.· Cancer· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.